Australian
Clinical Trials Alliance
|
|
The AVATAR Group is now a member of the Australian Clinical
Trials Alliance (ACTA). By building collaborative networks and partnerships, practising clinician researchers
can come together to identify important clinical questions and design large multicentre clinical trials
to answer them. ACTA has a strong focus on investigator-initiated trials that can provide unbiased, high-quality
scientific evidence of the effectiveness or cost effectiveness of interventions. To find out more, visit
the ACTA website: http://www.clinicaltrialsalliance.org.au/
|
Congratulations to Dr
Heather Reynolds who has been appointed to the position of Chair, Professional Standards Council /
Chief Standards Editor 2016-2019 for the Australian College of Perianaesthesia Nurses (ACPAN).
|
Successful Study Completion
|
|
Emily Larsen is a Senior Research Assistant with AVATAR, having begun her work with the group
in 2012. She commenced studying a Graduate Diploma of Health Research in 2013, under the supervision of
Professor Samantha Keogh and Professor Claire Rickard, which was completed in July 2016. As a component
of Emily's studies she undertook a qualitative research project exploring patients' lived experience of
peripheral IV insertion within a medical/surgical inpatient setting. Ten patients were sampled from the
medical/surgical units of the Royal Brisbane and Women's Hospital between May 2015 and September 2015.
Semi-structured interviews were conducted and analysed using a hermeneutic-phenomenological approach.
The interviews varied in duration from five to 26 minutes. Patients were asked one initial question 'what
has been your experience of IV insertion?' and further questions developed from the dialogue. Four key
themes developed from the thematic analysis including 'communication between the patient and the inserter';
'technique of device insertion'; 'competence of the inserter'; and 'location of the device.' We look
forward to sharing the results of this research with you all soon.
|
Organisations are finally coming together to work on best practice for vascular
access devices; a unified, persistent approach to patient assessment and
research will pay off.
Please
click here to read Samantha Keogh's
interview in Nursing Review.
|
Improving
patient care in China
|
|
| (from left to right) Dr Wan Qiaoqin;
Dr Guo GuiFang, Head of School of Nursing at Peking University; Dr Frances Lin (Griffith University);
and Professor Shang ShaoiMei of Peking University. Dr Lin receives the "Excellent Alumni Award" certificate. |
|
|
|
Dr Frances Lin has received a research fellowship from the Griffith University- Peking University
Collaborative Research Scheme Grant. Click
here to read about her collaborative work in China, which includes her research on PIVC and the OMG
study during the trip.
|
World Congress
on Vascular Access in Lisbon
|
|
The AVATAR Group would like to extend a huge thank you to
our industry partner, 3M who provided financial support for the team to attend the World Congress on Vascular
Access in Lisbon, Portugal, in June. This was an excellent opportunity to showcase all of our great work
and network with our vascular access colleagues from around the globe.
Front row (from left to right): Tricia
Kleidon, Dr Heather Reynolds, Prof Marie Cooke
Back row (from left to right): Emily Larsen, Prof
Claire Rickard, Nicole Marsh, Amanda Corley
(All from the AVATAR Group)
Gillian Ray-Barruel (AVATAR Group),
Tim Jackson, Dr Matt Jones, Gemma Oliver (UK)
Dr Vineet Chopra at WoCoVA
|
Over 700 people have completed the AVATAR IV consumer surveys
(adult and child). Please keep spreading the word!
http://bit.ly/2bxlJwS
The Alliance for Vascular Access Teaching and Research (AVATAR) group at Griffith University
specializes in research to prevent intravascular (IV) complications.
We are interested in the
experience of having an intravenous cannula (also called an IV or a 'drip').
An IV cannula
is a small plastic tube inserted into a vein in the hand, arm or leg and left in place for a while so
you (or your child) could receive medications, fluids, or blood.
Invitation to Adults
If
you are over the age of 18 years and have any experience of having an IV in the last 5 years, please use
the link below to answer 10 brief questions.
https://prodsurvey.rcs.griffith.edu.au/prodls190/index.php?sid=79896&
lang=en
Invitation to adults with children under 18 years
If you have had a child
(less than 18 years of age) who has experienced having an IV in the last 5 years, please use the link
below to answer 10 brief questions.
https://prodsurvey.rcs.griffith.edu.au/prodls190/index.php?sid=93565&
lang=en
This survey is voluntary and anonymous, and your responses will help us learn
more about the patient's experience of having an IV.
If you have questions about either survey,
please contact Professor Marie Cooke
Tel: 07 3735 5253
Email: m.cooke@griffith.edu.au
|
Education and Evidence Based
Practice Update
|
|
Australian Vascular Access Society Second
Annual Scientific Meeting and World Congress on Vascular Access Special Event, Perth, Australia, May 1012,
2017
Check out the promo! See you in Perth!
http://www.avatargroup.org.au/avas---wocova-2017.html
To learn more about the AVAS & WoCoVA 2017 Scientific Meeting, please click
here.
|
The AVATAR Group relies on competitive research funding
from government and charitable organizations, as well as donations from individuals and industry. We receive
no recurrent funding from any source.
Medtronic Infection Control Scholarship.
Australasian College of Infection Prevention and Control Early Career Grant. Choudhury N (CI). Emergence
of Antibacterial resistance associated with the use of antimicrobial impregnated dressings (the RACE study).
$12,000
Qld Emergency Medicine Research Foundation. Scott M, Bugden S,
Rickard C, Mervin C. The Value of Avoiding the Pain of IV Catheter Failure. $30,550
Angiodynamics Investigator-Initiated Grant 2016. Rickard C, Ullman A, Kleidon
T. Peripherally Inserted Central Catheter OutcoMes PolyurethAne veRsus Endexo (PIC COMPARE) AUD$86,800
Centurion Unrestricted Donation 2016. Rickard C. Ullman A, Marsh N. Secure
My Intravascular Line Effectively (the SMILE Trial). USD$208,000 (AUD $275,102.74)
3M
Unrestricted Donation 2016. Rickard CM. Support to AVATAR Team to present research at the
World Congress on Vascular Access in Portugal, 2016. US$15,000 (AUD $20,415.68)
BD
Unrestricted Donation 2016. Rickard CM. Support to AVATAR Group to present their research
at conferences in 2016. $40,000
|
Catch up with all the latest AVATAR publications here:
http://www.avatargroup.org.au/publications.html
Keogh S, Flynn J, Marsh N, Mihala G, Rickard CM. Varied flushing frequency and volume
to prevent peripheral intravenous catheter failure: a pilot, factorial randomised controlled trial in
adult medical-surgical hospital patients. Trials. July 2016. 17(1): 348.doi: 10.1186/s13063-016-1470-6
CONCLUSION: Neither increased flushing volume nor frequency significantly altered the risk of
PIVC failure. Female gender, hand/posterior wrist placement and episodes of access (flushes and medication)
may be more important. Larger, definitive trials are feasible and required.
Rickard C.
BJN Awards 2016: IV therapy. Br J Nurs. 2016 Jul 28;25(14):S33-4.
Professor
Claire Rickard was awarded second place in the BJN Awards 2016 for IV Therapy Nurse of the Year. Here
she talks about the work she has done to be recognised in this field.
Rickard CM, Edwards M, Spooner
AJ, Mihala G, Marsh N, Best J, Wendt T, Rapchuk I, Gabriel S, Thomson B, Corley A, Fraser JF. A
four-arm randomised controlled pilot trial of innovative solutions for jugular central venous access device
securement in 221 cardiac
surgical patients. Journal of Critical Care. 2016 June.
Conclusions: Jugular CVAD securement is challenging in postcardiac surgical patients who are coagulopathic
and mobilized early. Tissue Adhesive (TA) + Simple Polyurethane (SPU) was ineffective for CVAD securement
and is not recommended. Suture + TA + SPU appeared promising, with zero CVAD failure observed. Future
trials should resolve uncertainty about the
comparative effect of suture + TA + SPU, suture + Absorbent
Dressing (AD), and Sutureless
Securement Device (SSD) + SPU vs suture + BPU.
Zhang
L, Cao S, Marsh N, Ray-Barruel G, Flynn J, Larsen E, Rickard CM. Infection risks associated
with peripheral vascular catheters. Journal of Infection Prevention. July 2016. *Editor's
choice*
Results: It is estimated 3080% of hospitalised patients receive at least one PVC during
a hospital stay. Despite their prevalence, PVCs are not benign devices, and the high number inserted annually
has resulted in serious catheter-related bloodstream infections and significant morbidity, prolonged hospital
stay and increased healthcare costs. To date, PVC infections have been under-evaluated. Most studies focus
on central venous catheter rather than PVC-associated bloodstream infections. Risks associated with PVC
infection must be addressed.
Ullman AJ, Kleidon T, Gibson V, Long DA, Williams T, MCBride
C, Hallahan A, Mihala G, Cooke M, Rickard CM. Central venous Access device SeCurement And
Dressing Effectiveness in paediatrics (the CASCADE Junior Trials): protocols of pilot randomised controlled
trials in PICCs, tunnelled, and non-tunnelled devices. BMJ Open. June 2016;6(6):e011197.
METHODS AND ANALYSIS: Three feasibility randomised, controlled trials are to be undertaken at
the Royal Children's Hospital and the Lady Cilento Children's Hospital, Brisbane, Australia to compare
current practice with sutureless securement devices, integrated securement dressings and tissue adhesive.
In total, 328 paediatric patients requiring a peripherally inserted central catheter (n=100); non-tunnelled
CVAD (n=180) and tunnelled CVAD (n=48) will be recruited. Primary outcomes are study feasibility (eligibility,
recruitment, retention, attrition, missing data, parent/staff satisfaction and effect size). CVAD failure
and complication (catheter-associated bloodstream infection, local infection, venous thrombosis, occlusion,
dislodgement and breakage) will be compared between groups.
|
If you no longer wish to
receive communication from us, please reply to this email with unsubscribe in the subject
line.
|
|
|
